PIM
MDCO

Platinum Investment Management’s Medicines Co MDCO Stock Holding History

Platinum Investment Management’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-36,053
Closed -$1.8M – 107
2019
Q3 		$1.8M Sell
36,053
-10,760
-23% -$429K 0.04% 64
2019
Q2 		$1.71M Buy
+46,813
New +$1.53M 0.04% 68

Other funds holding MDCO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

Platinum Investment Management's MDCO Position: Q4 2019 in Review

Platinum Investment Management sold out of Medicines Co (MDCO) in Q4 2019, closing a stake of 36,053 shares — an estimated $1.8M sold.

Platinum Investment Management first reported a position in MDCO in Q2 2019 and held it in 2 quarters. The position peaked at $1.8M in Q3 2019. 284 funds tracked by Wall St. Rank hold MDCO as of Q4 2019.

  • Platinum Investment Management reported no remaining Medicines Co position as of Q4 2019 after selling out during the quarter.
  • Platinum Investment Management sold 36,053 Medicines Co shares in Q4 2019, an estimated $1.8M.
  • Platinum Investment Management first reported a position in Medicines Co in Q2 2019 and held it in 2 quarters.
  • Platinum Investment Management's Medicines Co position peaked at $1.8M in Q3 2019.
  • 284 funds tracked by Wall St. Rank held Medicines Co as of Q4 2019.

Based on Platinum Investment Management's 13F filing for Q4 2019, filed 13 Feb 2020.